{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:17:36Z","timestamp":1783556256040,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04973-8","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:06:40Z","timestamp":1778936800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel limited-dose C5 inhibitor add-on as rescue therapy for refractory NMOSD attacks: a practical alternative to conventional multi-dose regimens"],"prefix":"10.1186","volume":"26","author":[{"given":"Dianjia","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dantao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"10","key":"4973_CR1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","volume":"20","author":"A Uzawa","year":"2024","unstructured":"Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S. NMOSD and MOGAD: an evolving disease spectrum. Nat Rev Neurol. 2024;20(10):602\u201319. https:\/\/doi.org\/10.1038\/s41582-024-01014-1.","journal-title":"Nat Rev Neurol"},{"key":"4973_CR2","doi-asserted-by":"publisher","first-page":"731835","DOI":"10.3389\/fneur.2021.731835","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang J, Zhou Y, Xie H, Duan R, Jing L, et al. Analysis of Predictive Risk Factors in Aquaporin-4-IgG Positive Highly Active Neuromyelitis Optica Spectrum Disorders. Front Neurol. 2021;12:731835. https:\/\/doi.org\/10.3389\/fneur.2021.731835.","journal-title":"Front Neurol"},{"issue":"3","key":"4973_CR3","doi-asserted-by":"publisher","first-page":"e70049","DOI":"10.1111\/ene.70049","volume":"32","author":"P Siriratnam","year":"2025","unstructured":"Siriratnam P, Rocchi C, Gibbons E, Kelly P, Linaker S, Huda S. Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD? Eur J Neurol. 2025;32(3):e70049. https:\/\/doi.org\/10.1111\/ene.70049.","journal-title":"Eur J Neurol"},{"issue":"8","key":"4973_CR4","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.3390\/ijms26083585","volume":"26","author":"R Yamasaki","year":"2025","unstructured":"Yamasaki R. Microglia\/Macrophages in Autoimmune Demyelinating Encephalomyelitis (Multiple Sclerosis\/Neuromyelitis Optica). Int J Mol Sci. 2025;26(8):3585. https:\/\/doi.org\/10.3390\/ijms26083585.","journal-title":"Int J Mol Sci"},{"key":"4973_CR5","doi-asserted-by":"publisher","first-page":"1011579","DOI":"10.3389\/fneur.2022.1011579","volume":"13","author":"G Fadda","year":"2022","unstructured":"Fadda G, Flanagan EP, Cacciaguerra L, Jitprapaikulsan J, Solla P, Zara P, et al. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol. 2022;13:1011579. https:\/\/doi.org\/10.3389\/fneur.2022.1011579.","journal-title":"Front Neurol"},{"issue":"2","key":"4973_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/NRR.NRR-D-23-01325","volume":"20","author":"L Xu","year":"2025","unstructured":"Xu L, Xu H, Tang C. Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis. Neural Regen Res. 2025;20(2):354\u201365. https:\/\/doi.org\/10.4103\/NRR.NRR-D-23-01325.","journal-title":"Neural Regen Res"},{"issue":"1","key":"4973_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021;18(1):208. https:\/\/doi.org\/10.1186\/s12974-021-02249-1.","journal-title":"J Neuroinflammation"},{"key":"4973_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-323-90887-0.00015-8","volume":"214","author":"I Lotan","year":"2026","unstructured":"Lotan I, Anderson M, Levy M. Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Handb Clin Neurol. 2026;214:255\u201367. https:\/\/doi.org\/10.1016\/B978-0-323-90887-0.00015-8.","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"4973_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tmrv.2022.06.008","volume":"36","author":"I Lotan","year":"2022","unstructured":"Lotan I, Levy M. New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder. Transfus Med Rev. 2022;36(4):230\u20132. https:\/\/doi.org\/10.1016\/j.tmrv.2022.06.008.","journal-title":"Transfus Med Rev"},{"issue":"4","key":"4973_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.rdc.2017.06.007","volume":"43","author":"SL Patterson","year":"2017","unstructured":"Patterson SL, Goglin SE. Neuromyelitis Optica. Rheum Dis Clin North Am. 2017;43(4):579\u201391. https:\/\/doi.org\/10.1016\/j.rdc.2017.06.007.","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"4973_CR11","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijms22062801","volume":"22","author":"M Waliszewska-Pros\u00f3\u0142","year":"2021","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Chojdak-\u0141ukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects. Int J Mol Sci. 2021;22(6):2801. https:\/\/doi.org\/10.3390\/ijms22062801.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4973_CR12","doi-asserted-by":"publisher","first-page":"e561","DOI":"10.1212\/NXI.0000000000000561","volume":"6","author":"W Zhu","year":"2019","unstructured":"Zhu W, Wang Z, Hu S, Gong Y, Liu Y, Song H, et al. Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e561. https:\/\/doi.org\/10.1212\/NXI.0000000000000561.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"4973_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1900866.","journal-title":"N Engl J Med"},{"issue":"6","key":"4973_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","volume":"89","author":"DM Wingerchuk","year":"2021","unstructured":"Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, et al. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol. 2021;89(6):1088\u201398. https:\/\/doi.org\/10.1002\/ana.26049.","journal-title":"Ann Neurol"},{"issue":"1","key":"4973_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/sjopt.sjopt_102_23","volume":"38","author":"N Tisavipat","year":"2023","unstructured":"Tisavipat N, Juan HY, Chen JJ. Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Saudi J Ophthalmol. 2023;38(1):2\u201312. https:\/\/doi.org\/10.4103\/sjopt.sjopt_102_23.","journal-title":"Saudi J Ophthalmol"},{"issue":"1","key":"4973_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40478-025-02019-7","volume":"13","author":"KS Given","year":"2025","unstructured":"Given KS, Acker EG, Macklin WB, Carlin D, Owens GP, Bennett JL. Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica. Acta Neuropathol Commun. 2025;13(1):129. https:\/\/doi.org\/10.1186\/s40478-025-02019-7.","journal-title":"Acta Neuropathol Commun"},{"key":"4973_CR17","doi-asserted-by":"publisher","first-page":"1645401","DOI":"10.3389\/fimmu.2025.1645401","volume":"16","author":"Q Zhuang","year":"2025","unstructured":"Zhuang Q, Huang W, ZhangBao J, Wang Z, Zhou L, Li X, et al. Eculizumab for the acute attack of neuromyelitis optica spectrum disorder. Front Immunol. 2025;16:1645401. https:\/\/doi.org\/10.3389\/fimmu.2025.1645401.","journal-title":"Front Immunol"},{"issue":"11","key":"4973_CR18","doi-asserted-by":"publisher","first-page":"e73205","DOI":"10.7759\/cureus.73205","volume":"16","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Masaki K, Tanaka E, Matsushita T, Isobe N. The Efficacy of Eculizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study. Cureus. 2024;16(11):e73205. https:\/\/doi.org\/10.7759\/cureus.73205.","journal-title":"Cureus"},{"issue":"10","key":"4973_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.neurol.2024.09.001","volume":"180","author":"A San-Galli","year":"2024","unstructured":"San-Galli A, Chaumont H, Bourgeois Q, Roge J, Lobjois Q, Cabre P. Eculizumab as rescue therapy in a context of dramatic NMOSD attack: Report of two cases. Rev Neurol (Paris). 2024;180(10):995\u20137. https:\/\/doi.org\/10.1016\/j.neurol.2024.09.001.","journal-title":"Rev Neurol (Paris)"},{"key":"4973_CR20","doi-asserted-by":"publisher","first-page":"951423","DOI":"10.3389\/fneur.2022.951423","volume":"13","author":"S Chatterton","year":"2022","unstructured":"Chatterton S, Parratt JDE, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report. Front Neurol. 2022;13:951423. https:\/\/doi.org\/10.3389\/fneur.2022.951423.","journal-title":"Front Neurol"},{"issue":"5","key":"4973_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/13524585241283650","volume":"31","author":"RH Soni","year":"2025","unstructured":"Soni RH, Garcia M, Oak E, Applbaum EJ, Rajagopalan L, Krupp LB, et al. Acute eculizumab treatment in a pediatric patient with AQP4-IgG+ NMOSD. Mult Scler. 2025;31(5):612\u20134. https:\/\/doi.org\/10.1177\/13524585241283650.","journal-title":"Mult Scler"},{"issue":"2","key":"4973_CR22","doi-asserted-by":"publisher","first-page":"e200548","DOI":"10.1212\/NXI.0000000000200548","volume":"13","author":"PS Rommer","year":"2026","unstructured":"Rommer PS, Jiang W, Nolte JP, Mikami T, De Seze J, S\u00e1nchez P, et al. Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series. Neurol Neuroimmunol Neuroinflamm. 2026;13(2):e200548. https:\/\/doi.org\/10.1212\/NXI.0000000000200548.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"4973_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389. https:\/\/doi.org\/10.1212\/WNL.0000000000001729.","journal-title":"Neurology"},{"key":"4973_CR24","doi-asserted-by":"publisher","first-page":"175628642311624","DOI":"10.1177\/17562864231162420","volume":"16","author":"W Zhang","year":"2023","unstructured":"Zhang W, Jiao Y, Cui L, Zhang Y, Jiao J, Jin M, et al. Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study. Ther Adv Neurol Disord. 2023;16:17562864231162420. https:\/\/doi.org\/10.1177\/17562864231162420.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"4973_CR25","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"issue":"7","key":"4973_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00415-025-13180-3","volume":"272","author":"S Samadzadeh","year":"2025","unstructured":"Samadzadeh S, Chan F, Francis A, Sani L, Paul F, Asgari N, et al. The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD. J Neurol. 2025;272(7):453. https:\/\/doi.org\/10.1007\/s00415-025-13180-3.","journal-title":"J Neurol"},{"issue":"6","key":"4973_CR27","doi-asserted-by":"publisher","first-page":"e963","DOI":"10.1111\/aos.14659","volume":"99","author":"G Moussa","year":"2021","unstructured":"Moussa G, Bassilious K, Mathews N. A novel excel sheet conversion tool from Snellen fraction to LogMAR including \u2018counting fingers\u2019, \u2018hand movement\u2019, \u2018light perception\u2019 and \u2018no light perception\u2019 and focused review of literature of low visual acuity reference values. Acta Ophthalmol. 2021;99(6):e963\u20135. https:\/\/doi.org\/10.1111\/aos.14659.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"4973_CR28","doi-asserted-by":"publisher","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","volume":"10","author":"F Paul","year":"2023","unstructured":"Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, et al. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. https:\/\/doi.org\/10.1212\/NXI.0000000000200124.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"4973_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206\u201316. https:\/\/doi.org\/10.1002\/ana.24554.","journal-title":"Ann Neurol"},{"issue":"10","key":"4973_CR30","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1002\/acn3.52188","volume":"11","author":"S Wang","year":"2024","unstructured":"Wang S, Xue M, Wang J, Wu R, Shao Y, Luo K, et al. Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase. Ann Clin Transl Neurol. 2024;11(10):2731\u201344. https:\/\/doi.org\/10.1002\/acn3.52188.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"4973_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrd2369","volume":"6","author":"CJ Parker","year":"2007","unstructured":"Parker CJ, Kar S, Kirkpatrick P, Eculizumab. Nat Rev Drug Discov. 2007;6(7):515\u20136. https:\/\/doi.org\/10.1038\/nrd2369.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4973_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"Pt B","key":"4973_CR33","doi-asserted-by":"publisher","first-page":"113234","DOI":"10.1016\/j.intimp.2024.113234","volume":"142","author":"W Zhang","year":"2024","unstructured":"Zhang W, Cui L, Jiao J, Zhang Y, Ma C, Peng D, et al. Decreased NETosis-related regulators in neuromyelitis optica spectrum disorders after plasma exchange. Int Immunopharmacol. 2024;142(Pt B):113234. https:\/\/doi.org\/10.1016\/j.intimp.2024.113234.","journal-title":"Int Immunopharmacol"},{"key":"4973_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","volume":"27","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019;27:412\u20138. https:\/\/doi.org\/10.1016\/j.msard.2018.12.002.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"4973_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","volume":"21","author":"L Pandit","year":"2015","unstructured":"Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015;21(7):845\u201353. https:\/\/doi.org\/10.1177\/1352458515572406.","journal-title":"Mult Scler"},{"issue":"2","key":"4973_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cells8020090","volume":"8","author":"S Mader","year":"2019","unstructured":"Mader S, Brimberg L. Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. Cells. 2019;8(2):90. https:\/\/doi.org\/10.3390\/cells8020090.","journal-title":"Cells"},{"issue":"5","key":"4973_CR37","doi-asserted-by":"publisher","first-page":"e213399","DOI":"10.1212\/WNL.0000000000213399","volume":"104","author":"E Maillart","year":"2025","unstructured":"Maillart E, Dubessy AL, Shor N, Piljan M, Decombe R, Lubetzki C, et al. Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder. Neurology. 2025;104(5):e213399. https:\/\/doi.org\/10.1212\/WNL.0000000000213399.","journal-title":"Neurology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04973-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:54:09Z","timestamp":1783554849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04973-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4973"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04973-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8755894\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki, the study was approved by the Institutional Review Board of China\u2013Japan Friendship Hospital (Approval No. 2024-KY-242).Informed consent to participate was obtained from all the participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participants have provided written informed consent for their personal or clinical details and any identifiable images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"439"}}